Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

Rhea-AI Summary

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call on November 15, 2022, at 8:30 a.m. ET to report third-quarter financial results ending September 30, 2022. The call will provide a business overview and is accessible via phone or webcast. Bio-Path is recognized for its DNAbilize® technology, fostering a pipeline of targeted RNAi nanoparticle drugs. Key products include prexigebersen and BP1002, aimed at treating blood cancers and solid tumors. An IND for BP1003 is anticipated to be filed by early 2023.

Positive

• The company is advancing its pipeline with lead candidate prexigebersen in a Phase 2 study for blood cancers.
• FDA clearance for BP1001-A allows Phase 1 studies in solid tumors to commence in 2022.
• An IND application for BP1003 is expected in 2022 or Q1 2023.

Negative

• None.

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:
                        
Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings report their Q3 2022 financial results?

Bio-Path Holdings will report their Q3 2022 financial results on November 15, 2022.

What is the significance of the DNAbilize® technology for Bio-Path Holdings?

DNAbilize® technology allows Bio-Path to develop targeted nucleic acid cancer drugs, enhancing treatment options for patients.

What are the key products being developed by Bio-Path Holdings?

Key products include prexigebersen, BP1001-A, and BP1002, targeting various cancers.

Is there an upcoming IND filing from Bio-Path Holdings?

Yes, an IND filing for BP1003 is expected in late 2022 or early 2023.